<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075824</url>
  </required_header>
  <id_info>
    <org_study_id>BO42451</org_study_id>
    <secondary_id>2020-004839-25</secondary_id>
    <nct_id>NCT05075824</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)</brief_title>
  <acronym>CROSSWALK-c</acronym>
  <official_title>A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab&#xD;
      compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">January 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of medical facility VOEs (AVR)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of home VOE</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of uncomplicated medical facility VOE</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of Acute Chest Syndrome (ACS)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of days hospitalized for medical facility VOE</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of days hospitalized for treatment of non-VOE complications of SCD</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first medical facility VOE from randomization</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin-creatinine ratio</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tricuspid Regurgitant Jet Velocity (TRV)</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with TRV &gt;2.5 m/s</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue Score in Adults</measure>
    <time_frame>Baseline up to Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Crovalimab over time</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies to Crovalimab</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Crovalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crovalimab</intervention_name>
    <description>Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight &gt;= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight &gt;= 100 kg). Dosing schedule will be as per Arm Description.</description>
    <arm_group_label>Crovalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;=40 kg.&#xD;
&#xD;
          -  Male or female with confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia)&#xD;
             or HbSÎ²0 (SCD genotype of sickle cell beta zero thalassemia).&#xD;
&#xD;
          -  Two or more (&gt;=2) to &lt;=10 documented VOEs in the 12 months prior to randomisation.&#xD;
&#xD;
          -  If receiving concurrent SCD-directed therapy, the participant must have been on a&#xD;
             stable dose for a minimum of 3 months prior to study enrollment. There should be no&#xD;
             plans to modify the participants' dosing throughout the study duration, other than for&#xD;
             safety reasons.&#xD;
&#xD;
          -  If receiving erythropoietin, the participant must have been prescribed this medication&#xD;
             for the preceding 3 months and be dose-stabilised for at least 3 months prior to study&#xD;
             enrollment.&#xD;
&#xD;
          -  Vaccination against N. meningitides and Vaccinations against H. influenza type B and&#xD;
             S. pneumonia.&#xD;
&#xD;
          -  Participants who have been vaccinated (partially or in full) against SARS-CoV-2 with a&#xD;
             locally approved vaccine are eligible to be enrolled in the study, 3 days or longer&#xD;
             after inoculation.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or use&#xD;
             contraception during the treatment period and for 6 months after the final dose of&#xD;
             study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hematopoietic stem cell transplant.&#xD;
&#xD;
          -  Participating in a chronic transfusion program and/or planning on undergoing an&#xD;
             exchange transfusion during the duration of the study.&#xD;
&#xD;
          -  History of hypersensitivity, allergic, or anaphylactic reactions to any ingredient&#xD;
             contained in the study treatment.&#xD;
&#xD;
          -  Received active treatment on another investigational trial within 28 days (or within&#xD;
             five half-lives of that agent, whichever is greater) prior to screening visit, or&#xD;
             plans to participate in another investigational drug trial.&#xD;
&#xD;
          -  Hemoglobin &lt;6 g/dL.&#xD;
&#xD;
          -  Known or suspected hereditary complement deficiency.&#xD;
&#xD;
          -  Active systemic bacterial, viral, or fungal infection within 14 days before first drug&#xD;
             administration.&#xD;
&#xD;
          -  Presence of fever (&gt;=38 degrees Celsius) within 7 days before the first drug&#xD;
             administration.&#xD;
&#xD;
          -  Immunised with a live attenuated vaccine within 1 month before first drug&#xD;
             administration.&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             6 months after the final dose of study treatment.&#xD;
&#xD;
          -  Known HIV infection with documented CD4 count &lt;200 cells/microliter within 24 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  History of N. meningitidis infection within the prior 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO42451 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio MaraÃ±Ã³n; OncologÃ­a y HematologÃ­a PediÃ¡tricas y del Adolescente</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Italy</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaso-occlusive episodes</keyword>
  <keyword>Pain crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

